NCT01023282View on ClinicalTrials.gov

Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Parkinson's DiseaseTolerability
Interventions
DRUG

ACR325

Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks

DRUG

Placebo

Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks

Trial Locations (2)

D-34128

Paracelsus-Elena-Klinik, Kassel

D-35039

Klinik für Neurologie, Philipps-Universität Marburg, Marburg

Sponsors

Lead Sponsor

NeuroSearch A/S
All Listed Sponsors
lead

NeuroSearch A/S

INDUSTRY

NCT01023282 - Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients | Biotech Hunter | Biotech Hunter